Drugs / ASP4070
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02469688 | Jun → Nov 2015 | seasonal allergic rhinitis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03101267 | Apr 2017 → Jan 2018 | seasonal allergic rhinitis | Astellas Pharma Inc | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP4070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02469688 ↗ |
| Modality | Vaccine | “ASP4070 intramuscular vaccination group” NCT02469688 ↗ |
| Route | Intramuscular | “intramuscular or intradermal” NCT02469688 ↗ |